166 related articles for article (PubMed ID: 34882988)
21. Increased Serum B Cell Activating Factor and a Proliferation-inducing Ligand Are Associated with Interstitial Lung Disease in Patients with Juvenile Dermatomyositis.
Kobayashi N; Kobayashi I; Mori M; Sato S; Iwata N; Shigemura T; Agematsu K; Yokota S; Koike K
J Rheumatol; 2015 Dec; 42(12):2412-8. PubMed ID: 26472413
[TBL] [Abstract][Full Text] [Related]
22. Successful Treatment of Rapidly Progressive Interstitial Lung Disease in Juvenile Dermatomyositis.
Ciaglia K; Ghawji M; Caraballo M; Sloan E
Pediatrics; 2024 Mar; 153(3):. PubMed ID: 38361479
[TBL] [Abstract][Full Text] [Related]
23. Anti-MDA5 antibody-positive dermatomyositis with rapidly progressive interstitial lung disease: report of two cases.
Mehta AA; Paul T; Cb M; Haridas N
BMJ Case Rep; 2021 Apr; 14(4):. PubMed ID: 33910791
[TBL] [Abstract][Full Text] [Related]
24. Comprehensive assessment of myositis-specific autoantibodies in polymyositis/dermatomyositis-associated interstitial lung disease.
Hozumi H; Fujisawa T; Nakashima R; Johkoh T; Sumikawa H; Murakami A; Enomoto N; Inui N; Nakamura Y; Hosono Y; Imura Y; Mimori T; Suda T
Respir Med; 2016 Dec; 121():91-99. PubMed ID: 27888997
[TBL] [Abstract][Full Text] [Related]
25. Clinical analysis and outcome of interstitial lung disease complicated with juvenile dermatomyositis and juvenile polymyositis.
Sato S; Uejima Y; Nanbu M; Suganuma E; Takano T; Tanaka R; Kabuki T; Oguma E; Oh-Ishi T; Kawano Y
Mod Rheumatol; 2017 Jul; 27(4):652-656. PubMed ID: 27588444
[TBL] [Abstract][Full Text] [Related]
26. Anti-SAE autoantibody-positive Japanese patient with juvenile dermatomyositis complicated with interstitial lung disease - a case report.
Kishi T; Tani Y; Okiyama N; Mizuochi K; Ichimura Y; Harigai M; Nagata S; Miyamae T
Pediatr Rheumatol Online J; 2021 Mar; 19(1):34. PubMed ID: 33740993
[TBL] [Abstract][Full Text] [Related]
27. Tofacitinib for new-onset adult patients with anti-melanoma differentiation-associated 5 gene antibody positive dermatomyositis.
Wang Y; Luo J; Lv X; Li Y; An Q; Mo L; Hu N; Zhang J; Wang J; Tian J; Pu D; Hao Z; He L
Clin Rheumatol; 2023 Jul; 42(7):1847-1853. PubMed ID: 36929498
[TBL] [Abstract][Full Text] [Related]
28. Tofacitinib in interstitial lung disease complicated with anti-MDA5 antibody-positive dermatomyositis: A literature review.
Takanashi S; Kaneko Y; Takeuchi T
Mod Rheumatol; 2022 Jan; 32(1):231-237. PubMed ID: 33769925
[No Abstract] [Full Text] [Related]
29. Correlation between disease activity and serum ferritin in clinically amyopathic dermatomyositis with rapidly-progressive interstitial lung disease: a case report.
Yamada K; Asai K; Okamoto A; Watanabe T; Kanazawa H; Ohata M; Ohsawa M; Hirata K
BMC Res Notes; 2018 Jan; 11(1):34. PubMed ID: 29338781
[TBL] [Abstract][Full Text] [Related]
30. Serum neopterin as well as ferritin, soluble interleukin-2 receptor, KL-6 and anti-MDA5 antibody titer provide markers of the response to therapy in patients with interstitial lung disease complicating anti-MDA5 antibody-positive dermatomyositis.
Nishioka A; Tsunoda S; Abe T; Yoshikawa T; Takata M; Kitano M; Matsui K; Nakashima R; Hosono Y; Ohmura K; Mimori T; Sano H
Mod Rheumatol; 2019 Sep; 29(5):814-820. PubMed ID: 30449228
[No Abstract] [Full Text] [Related]
31. Treatment of MDA5-positive dermatomyositis complicated by gangrenous cholecystitis with tofacitinib.
Luo M; Chen L; He H; He F
Eur J Med Res; 2022 May; 27(1):68. PubMed ID: 35570320
[TBL] [Abstract][Full Text] [Related]
32. [Response of dermatomyositis with lung involvement to Janus kinase inhibitor treatment].
Hornig J; Weinhage T; Schmidt LH; Buerke B; Schneider U; Pavenstädt H; Becker H; Gabriëls G
Z Rheumatol; 2018 Dec; 77(10):952-957. PubMed ID: 30421033
[TBL] [Abstract][Full Text] [Related]
33. Rapidly progressive interstitial lung disease in a patient with anti-MDA5-positive amyopathic dermatomyositis.
Nandy A; Gaïni S; Sore P
Scand J Rheumatol; 2018 Jul; 47(4):334-335. PubMed ID: 29043891
[No Abstract] [Full Text] [Related]
34. Respiratory symptoms as initial manifestations of interstitial lung disease in clinically amyopathic juvenile dermatomyositis: a case report with literature review.
Xia J; Jiang G; Jin T; Shen Q; Ma Y; Wang L; Qian L
BMC Pediatr; 2021 Nov; 21(1):488. PubMed ID: 34732158
[TBL] [Abstract][Full Text] [Related]
35. A case of anti-MDA5-positive rapidly progressive interstitial lung disease in a patient with clinically amyopathic dermatomyositis ameliorated by rituximab, in addition to standard immunosuppressive treatment.
Koichi Y; Aya Y; Megumi U; Shunichi K; Masafumi S; Hiroaki M; Masahiko K; Shinsuke K; Manabu U; Kenichiro H; Fumiaki A; Nozomi A; Toshitaka M; Masayoshi Y; Chikako K; Yoshinao M; Tatsuo S; Masahiko K
Mod Rheumatol; 2017 May; 27(3):536-540. PubMed ID: 25698373
[TBL] [Abstract][Full Text] [Related]
36. Adolescent-onset anti-MDA5 antibody-positive juvenile dermatomyositis with rapidly progressive interstitial lung disease and spontaneous pneumomediastinum: a case report and literature review.
Yeung TW; Cheong KN; Lau YL; Tse KN
Pediatr Rheumatol Online J; 2021 Jun; 19(1):103. PubMed ID: 34193210
[TBL] [Abstract][Full Text] [Related]
37. Low positive titer of anti-melanoma differentiation-associated gene 5 antibody is not associated with a poor long-term outcome of interstitial lung disease in patients with dermatomyositis.
Sakamoto S; Okamoto M; Kaieda S; Fujimoto K; Nagata S; Tominaga M; Nakamura M; Zaizen Y; Nouno T; Koga T; Kawayama T; Kuwana M; Ida H; Hoshino T
Respir Investig; 2018 Nov; 56(6):464-472. PubMed ID: 30150008
[TBL] [Abstract][Full Text] [Related]
38. A Case of Refractory Interstitial Lung Disease in Anti-MDA5-Positive Dermatomyositis That Improved After Switching to Tofacitinib.
Hosokawa Y; Oiwa H
J Clin Rheumatol; 2021 Dec; 27(8S):S661-S662. PubMed ID: 33252394
[No Abstract] [Full Text] [Related]
39. Clinical significance of radiological patterns of HRCT and their association with macrophage activation in dermatomyositis.
Zuo Y; Ye L; Liu M; Li S; Liu W; Chen F; Lu X; Gordon P; Wang G; Shu X
Rheumatology (Oxford); 2020 Oct; 59(10):2829-2837. PubMed ID: 32065646
[TBL] [Abstract][Full Text] [Related]
40. Anti-MDA5 autoantibodies associated with juvenile dermatomyositis constitute a distinct phenotype in North America.
Mamyrova G; Kishi T; Shi M; Targoff IN; Huber AM; Curiel RV; Miller FW; Rider LG;
Rheumatology (Oxford); 2021 Apr; 60(4):1839-1849. PubMed ID: 33140079
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
